TPST

TPST

USD

Tempest Therapeutics Inc. Common Stock

$6.990-0.035 (-0.498%)

Real-time Price

Healthcare
Biotechnology
United States

Price Chart

Loading Chart...

Key Metrics

Market Metrics
Company Fundamentals
Trading Stats

Market Metrics

Open

$7.025

High

$7.230

Low

$6.650

Volume

0.01M

Company Fundamentals

Market Cap

24.6M

Industry

Biotechnology

Country

United States

Trading Stats

Avg Volume

0.06M

Exchange

NCM

Currency

USD

52-Week Range

Low $5.356Current $6.990High $49.27

Related News

GlobeNewswire

Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting

BRISBANE, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight

View more
Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting
GlobeNewswire

Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP

BRISBANE, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeutics to fight

View more
Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP
Analyst Upgrades

Tempest Weighs M&A, Analyst Sees A "Broken Story" Despite Phase 2 Liver Cancer Study Success

Tempest Therapeutics hires MTS Health to explore M&A and partnerships after Roche shows limited interest in its liver cancer program.

View more
Tempest Weighs M&A, Analyst Sees A "Broken Story" Despite Phase 2 Liver Cancer Study Success
Analyst Upgrades

Scotiabank Downgrades Tempest Therapeutics to Sector Perform, Lowers Price Target to $9

Scotiabank analyst George Farmer downgrades Tempest Therapeutics from Sector Outperform to Sector Perform and lowers the price target from $91 to $9.

View more
Scotiabank Downgrades Tempest Therapeutics to Sector Perform, Lowers Price Target to $9
Analyst Upgrades

HC Wainwright & Co. Downgrades Tempest Therapeutics to Neutral, Maintains Price Target to $16

HC Wainwright & Co. analyst Joseph Pantginis downgrades Tempest Therapeutics from Buy to Neutral and maintains the price target from $16 to $16.

View more
HC Wainwright & Co. Downgrades Tempest Therapeutics to Neutral, Maintains Price Target to $16
GlobeNewswire

Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value

Amezalpat (TPST-1120) is Phase 3-ready: completed FDA and EMA interactions for first-line pivotal study in hepatocellular carcinoma (HCC); global investigator support in placeAwarded both Orphan Drug & Fast Track